Aging-related rotenone-induced neurochemical and behavioral deficits: Role of SIRT2 and redox imbalance, and neuroprotection by AK-7

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2553-2563

  Wang, Xijin ^a   Guan, Qiang ^b   Wang, Meihua ^a   Yang, Liu ^a   Bai, Jie ^a   Yan, Zhiqiang ^c   Zhang, Yuhong ^b   Liu, Zhenguo ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Dopamine; Environmental toxin; Oxidative stress; Parkinson s disease; Sirtuin

Indexed keywords

AK 7; GLUTATHIONE; HYDROLASE INHIBITOR; MALONALDEHYDE; ROTENONE; SEROTONIN; SIRTUIN 2; UNCLASSIFIED DRUG; 3-(1-AZEPANYLSULFONYL)-N-(3-BROMPHENYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DOPAMINE; NEUROPROTECTIVE AGENT; SIRT2 PROTEIN, RAT; SULFONAMIDE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MALE; MIDBRAIN RAPHE NUCLEUS; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION STATE; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; RISK FACTOR; SUBSTANTIA NIGRA; ANIMAL; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

AGING; ANIMALS; BENZAMIDES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; MALE; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SIRTUIN 2; SUBSTANTIA NIGRA; SULFONAMIDES;

EID: 84929207829     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S81539     Document Type: Article

References (62)

1. Dauer W, Przedborski S. Parkinson’s disease: Mechanisms and models. Neuron. 2003;39(6):889-909.
2. Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm. 2010;117(8):971-979.
3. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA. 2014;311(16):1670-1683.
4. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 1999;22:123-144.
5. Kidd PM. Parkinson’s disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 2000;5(6):502-529.
6. Gao HM, Hong JS, Zhang W, Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson’s disease. J Neurosci. 2003;23(4):1228-1236.
7. Nelson M, Huggins T, Licorish R, Carroll MA, Catapane EJ. Effects of p-Aminosalicylic acid on the neurotoxicity of manganese on the dopaminergic innervation of the cilia of the lateral cells of the gill of the bivalve mollusc, Crassostrea virginica. Comp Biochem Physiol C Toxicol Pharmacol. 2010;151(2):264-270.
8. Wang X, Chen S, Ma G, Ye M, Lu G. Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev. 2005;126(12):1241-1254.
9. Wang X, Chen S, Ma G, Ye M, Lu G. Genistein protects dopaminergic neurons by inhibiting microglial activation. Neuroreport. 2005;16(3):267-270.
10. Wang XJ, Yan ZQ, Lu GQ, Stuart S, Chen SD. Parkinson disease IgG and C5a-induced synergistic dopaminergic neurotoxicity: Role of microglia. Neurochem Int. 2007;50(1):39-50.
11. Wang XJ, Liu WG, Zhang YH, Lu GQ, Chen SD. Effect of transplantation of c17.2 cells transfected with interleukin-10 gene on intracerebral immune response in rat model of Parkinson’s disease. Neurosci Lett. 2007;423(2):95-99.
12. Wang XJ, Zhang S, Yan ZQ, et al. Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: Roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Radic Biol Med. 2011;50(9):1094-1106.
13. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol. 2008;3:41-66.
14. Gureviciene I, Gurevicius K, Tanila H. Aging and alpha-synuclein affect synaptic plasticity in the dentate gyrus. J Neural Transm. 2009;116(1):13-22.
15. Hindle JV. Ageing, neurodegeneration and Parkinson’s disease. Age Ageing. 2010;39(2):156-161.
16. Ma L, Wei L, Wu F, Hu Z, Liu Z, Yuan W. Advances with microRNAs in Parkinson’s disease research. Drug Des Devel Ther. 2013;7:1103-1113.
17. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3(12):1301-1306.
18. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis. 2009;34(2):279-290.
19. Fleming SM, Zhu C, Fernagut PO, et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol. 2004;187(2):418-429.
20. Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res. 2002;136(1):317-324.
21. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2003;179(1):9-16.
22. Phinney AL, Andringa G, Bol JG, et al. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism Relat Disord. 2006;12(4):228-238.
23. Moldzio R, Radad K, Krewenka C, et al. Effects of epigallocatechin gallate on rotenone-injured murine brain cultures. J Neural Transm. 2010;117(1):5-12.
24. Gao HM, Hong JS, Zhang W, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 2002;22(3):782-790.
25. Dillin A, Kelly JW. Medicine. The yin-yang of sirtuins. Science. 2007;317(5837):461-462.
26. Harting K, Knöll B. SIRT2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology. Eur J Cell Biol. 2010;89(2-3):262-269.
27. Maxwell MM, Tomkinson EM, Nobles J, et al. The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum Mol Genet. 2011;20(20):3986-3996.
28. Milne JC, Denu JM. The Sirtuin family: Therapeutic targets to treat diseases of aging. Curr Opin Chem Biol. 2008;12(1):11-17.
29. Donmez G, Outeiro TF. SIRT1 and SIRT2: Emerging targets in neurodegeneration. EMBO Mol Med. 2013;5(3):344-352.
30. Yoo DY, Kim DW, Kim MJ, et al. Sodium butyrate, a histone deacetylase Inhibitor, ameliorates SIRT2-induced memory impairment, reduction of cell proliferation, and neuroblast differentiation in the dentate gyrus. Neurol Res. 2015;37(1):69-76.
31. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol. 2004;56(1):149-162.
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
33. Baldo BA, Sadeghian K, Basso AM, Kelley AE. Effects of selective dopamine D1 or D2 receptor blockade within nucleus accumbens subregions on ingestive behavior and associated motor activity. Behav Brain Res. 2002;137(1-2):165-177.
34. Outeiro TF, Marques O, Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta. 2008;1782(6): 363-369.
35. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460(7255):587-591.
36. Saunders LR, Verdin E. Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489-5504.
37. Kalle AM, Mallika A, Badiger J Alinakhi, Talukdar P, Sachchidanand. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun. 2010;401(1):13-19.
38. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell. 2006;126(2):257-268.
39. Gan L, Mucke L. 2008. Paths of convergence: Sirtuins in aging and neurodegeneration. Neuron. 2008;58(1):10-14.
40. de Oliveira RM, Pais TF, Outeiro TF. Sirtuins: common targets in aging and in neurodegeneration. Curr Drug Targets. 2010;11(10):1270-1280.
41. Orozco H, Matallana E, Aranda A. Wine yeast sirtuins and Gcn5p control aging and metabolism in a natural growth medium. Mech Ageing Dev. 2012;133(5):348-358.
42. Southwood CM, Peppi M, Dryden S, Tainsky MA, Gow A. Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem Res. 2007;32(2):187-195.
43. Pandithage R, Lilischkis R, Harting K, et al. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol. 2008;180(5):915-929.
44. Li W, Zhang B, Tang J, et al. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci. 2007;27(10):2606-2616.
45. Werner HB, Kuhlmann K, Shen S, et al. Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci. 2007;27(29):7717-7730.
46. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson’s disease. Science. 2007;317(5837):516-519.
47. Luthi-Carter R, Taylor DM, Pallos J, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A. 2010;107(17):7927-7932.
48. Taylor DM, Balabadra U, Xiang Z, et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem Biol. 2011;6(6):540-546.
49. Chopra V, Quinti L, Kim J, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Rep. 2012;2(6):1492-1497.
50. Pfister JA, Ma C, Morrison BE, D’Mello SR. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One. 2008;3(12):e4090.
51. Argüelles S, Cano M, Machado A, Ayala A. Effect of aging and oxidative stress on elongation factor-2 in hypothalamus and hypophysis. Mech Ageing Dev. 2011;132(1-2):55-64.
52. Cui H, Kong Y, Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct. 2012;2012:646354.
53. Sykora P, Wilson DM, Bohr VA. Base excision repair in the mammalian brain: Implication for age related neurodegeneration. Mech Ageing Dev. 2013;134(10):440-448.
54. Kamarudin MN, Mohd Raflee NA, Hussein SS, Lo JY, Supriady H, Abdul Kadir H. (R)-(+)-α-lipoic acid protected NG108-15 cells against H2O2-induced cell death through PI3K-Akt/GSK-3β pathway and suppression of NF-κβ-cytokines. Drug Des Devel Ther. 2014;8:1765-1780.
55. Navarro-Yepes J, Zavala-Flores L, Anandhan A, et al. Antioxidant gene therapy against neuronal cell death. Pharmacol Ther. 2014;142(2):206-230.
56. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem. 1989;52(2):381-389.
57. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord. 1994;9(1):92-97.
58. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11(1):81-128.
59. Ross BM, Moszczynska A, Erlich J, Kish SJ. Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: possible implications for Parkinson’s disease. Neuroscience. 1998;83(3):791-798.
60. Ferraro TN, Golden GT, DeMattei M, Hare TA, Fariello RG. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Neuropharmacology. 1986;25(9):1071-1074.
61. Han SH. Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol. 2009;5(3):120-125.
62. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins - novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008;7(10):841-853.